Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study
- PMID: 40874300
- DOI: 10.1111/dom.70049
Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study
Abstract
Aims: This study investigates the impact of the era of diabetes onset on the prevalence of diabetic retinopathy and albuminuria 15 years post-diagnosis in people living with type 1 diabetes (T1D) within a national healthcare system offering structured multidisciplinary endocrinology care.
Materials and methods: We analysed data of 2176 individuals diagnosed with T1D before age 30, comparing two cohorts based on diabetes onset period: group A (1985-1998) and group B (1998-2009). The prevalence of diabetic retinopathy and albuminuria was assessed using generalised estimating equations.
Results: Glycaemic control (haemoglobin A1C: 8.3% vs. 8.1%, p < 0.0001) and low density lipoprotein cholesterol (2.6 mmol/L vs. 2.5 mmol/L, p < 0.001) were poorer in group A, whereas obesity prevalence was higher in group B (12.8% vs. 17.4%, p < 0.01). Group A used more antihypertensive therapy (14.9% vs. 11.5%, p < 0.01), while group B used more lipid-lowering therapy (9.2% vs. 15.9%, p < 0.0001). The prevalence of diabetic retinopathy 15 years post-diagnosis significantly declined from 36.3% in 2001 to 21.1% in 2022 (p < 0.0001). This decrease was particularly pronounced in individuals with diabetes onset after 11 years of age. The prevalence of albuminuria, adjusted for age and sex, decreased from 14.9% in 2001 to 7.3% in 2022 (p < 0.05).
Conclusions: Individuals diagnosed with T1D after 1998 had fewer microvascular complications 15 years post-diagnosis, especially less retinopathy in those with diabetes onset after age 11. This decline highlights the impact of improved care.
Keywords: microvascular complications; real‐world data; type 1 diabetes.
© 2025 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3‐16. doi:10.1007/s00125‐018‐4711‐2
-
- Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30‐year follow‐up. Diabetes Care. 2016;39(5):686‐693. doi:10.2337/dc15‐1990
-
- Gregg EW, Li Y, Wang J, et al. Changes in diabetes‐related complications in the United States, 1990‐2010. N Engl J Med. 2014;370(16):1514‐1523. doi:10.1056/NEJMoa1310799
-
- Carstensen B, Rønn PF, Jørgensen ME. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996‐2016. BMJ Open Diabetes Res Care. 2020;8(1):e001071. doi:10.1136/bmjdrc‐2019‐001071
-
- Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407‐1418. doi:10.1056/NEJMoa1608664
Grants and funding
LinkOut - more resources
Full Text Sources